Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

2.

13-valent pneumococcal conjugate vaccine (PCV13).

Jefferies JM, Macdonald E, Faust SN, Clarke SC.

Hum Vaccin. 2011 Oct;7(10):1012-8. doi: 10.4161/hv.7.10.16794. Epub 2011 Oct 1. Review.

PMID:
21941097
3.

Pneumococcal serotype evolution in Western Europe.

Tin Tin Htar M, Christopoulou D, Schmitt HJ.

BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. Review.

5.

Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.

Paradiso PR.

Clin Infect Dis. 2011 May;52(10):1241-7. doi: 10.1093/cid/cir142. Review.

PMID:
21507921
6.

Prevnar 13, the new 13-valent pneumococcal conjugate vaccine.

Sucher AJ, Chahine EB, Nelson M, Sucher BJ.

Ann Pharmacother. 2011 Dec;45(12):1516-24. doi: 10.1345/aph.1Q347. Epub 2011 Nov 1. Review.

PMID:
22045904
7.

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children.

Esposito S, Principi N.

J Immunol Res. 2015;2015:591580. doi: 10.1155/2015/591580. Epub 2015 Aug 17. Review.

8.

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L.

BMC Infect Dis. 2012 Sep 7;12:207. doi: 10.1186/1471-2334-12-207. Review.

9.

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.

Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T.

Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. Review.

10.

Recent Developments and Future Directions of Pneumococcal Vaccine Recommendations.

Tromp KM, Campbell MW, Vazquez A.

Clin Ther. 2015 May 1;37(5):928-34. doi: 10.1016/j.clinthera.2015.03.025. Epub 2015 Apr 23. Review.

PMID:
25913921
11.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].

Duggan ST.

Drugs. 2010 Oct 22;70(15):1973-86. doi: 10.2165/11205110-000000000-00000. Review.

PMID:
20883054
12.

13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents.

Plosker GL.

Paediatr Drugs. 2013 Oct;15(5):403-23. doi: 10.1007/s40272-013-0047-z. Review.

PMID:
24030738
13.
14.

The pneumococcal conjugate vaccine.

Jacobson RM, Poland GA.

Minerva Pediatr. 2002 Aug;54(4):295-303. Review.

PMID:
12131865
15.

Novel pneumococcal serotypes 6C and 6D: anomaly or harbinger.

McEllistrem MC, Nahm MH.

Clin Infect Dis. 2012 Nov 15;55(10):1379-86. doi: 10.1093/cid/cis691. Epub 2012 Aug 16. Review.

16.

Pneumococcal conjugate vaccine for young children.

Selman S, Hayes D, Perin LA, Hayes WS.

Manag Care. 2000 Sep;9(9):49-52, 54, 56-7 passim. Review.

17.

Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.

Gruber WC, Scott DA, Emini EA.

Ann N Y Acad Sci. 2012 Aug;1263:15-26. doi: 10.1111/j.1749-6632.2012.06673.x. Epub 2012 Jul 25. Review.

PMID:
22830997
18.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults.

Sanford M.

Drugs. 2012 Jun 18;72(9):1243-55. doi: 10.2165/11209330-000000000-00000. Review.

PMID:
22686616
19.

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.

Plosker GL.

Drugs. 2015 Sep;75(13):1535-46. doi: 10.1007/s40265-015-0449-z. Review.

PMID:
26242768
20.

Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T.

Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):19-31. doi: 10.1007/s10096-014-2208-6. Epub 2014 Aug 23. Review. Erratum in: Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):415-6.

Supplemental Content

Support Center